



1. (Previously Presented) A compound represented by the formula:



wherein ring A represents benzene ring optionally having a further substituent,

-L- represents -O-, -NR^{3a}-, -S-, -SO-, -SO₂-, -SO₂NR^{3a}-, -SO₂NHCONR^{3a}-,

-SO₂NHC(=NH)NR^{3a}-, -C(=S)-,



or -CONR^{3a}-


wherein R^{3a} and R^{3b} represent independently hydrogen atom, cyano group,

hydroxy group, amino group, a C₁₋₆ alkyl group or a C₁₋₆ alkoxy group,

n represents an integer of 0 to 6,

R is hydrogen atom or a hydrocarbon group optionally having a substituent, and may be different in repetition of n,

R¹ represents a hydrocarbon group optionally having a substituent or a group represented by the formula:



wherein R⁷ represents a hydrocarbon group optionally having a substituent,

R² represents hydrogen atom, an acyl group, a hydrocarbon group optionally having a substituent or a heterocyclic group optionally having a substituent,


X represents a bond,

k and m are each independently an integer of 0 to 4 and $k + m = 4$,

or a salt thereof.

2. (Original) The compound according to claim 1, wherein n is an integer of 1 to 6.

3. (Original) The compound according to claim 1, wherein -L- is -O-, -S-, -SO-, -SO₂-, -CH₂-, -CHOH-,



4. (Original) The compound according to claim 1, wherein X is a bond and $k=m=2$.

5. (Original) The compound according to claim 1, wherein X is a bond, $k=3$ and $m=1$.

6. (Cancelled)

7. (Original) The compound according to claim 1, wherein R is hydrogen atom.

8. (Currently Amended) The compound according to claim 1, wherein n is an integer of 2 to 4.


9. (Original) The compound according to claim 1, wherein R¹ is a C₇₋₁₆ aralkyl group optionally having a substituent.

10. (Original) The compound according to claim 1, wherein R² is a C₇₋₁₆ aralkyl group optionally having a substituent.
11. (Original) The compound according to claim 1, wherein R is hydrogen atom, n is an integer of 2 to 4, and R¹ and R² are benzyl group optionally having a substituent.
12. (Previously Presented) A compound selected from the group consisting of
- 2-[(2-methylphenyl)methyl]-7-[2-[1-[[2-(trifluoromethyl)phenyl]methyl]-4-piperidinyl]ethoxy]-2,3,4,5-tetrahydro-1H-2-benzazepine,
- 2-[(2-methylphenyl)methyl]-8-[2-[1-[(4-chlorophenyl)methyl]-4-piperidinyl]ethoxy]-2,3,4,5-tetrahydro-1H-2-benzazepine,
- 3-[1-(phenylmethyl)-4-piperidinyl]-1-[3-(phenylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepine-7-yl]-1-propanone oxime,
- 2-[1-[3-(phenylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepine-7-yl]-3-[1-(phenylmethyl)-4-piperidinyl]propylidene]malononitrile,
- 3-(phenylmethyl)-7-[[2-[1-(phenylmethyl)-4-piperidinyl]ethyl]sulfonyl]-2,3,4,5-tetrahydro-1H-3-benzazepine,
- 7-[[2-[1-[(2-chlorophenyl)methyl]-4-piperidinyl]ethyl]sulfinyl]-3-(phenylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepine,
- 7-[[2-[1-[(4-chlorophenyl)methyl]-4-piperidinyl]ethyl]sulfinyl]-3-(phenylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepine,
- 7-[[2-[1-[(3-chlorophenyl)methyl]-4-piperidinyl]ethyl]sulfonyl]-3-(phenylmethyl)-2,3,4,5-tetrahydro-1H-3-benzazepine,

8-[3-[1-[[3-(4,5-dihydro-1H-2-imidazolyl)phenyl]methyl]-4-piperidinyl]propoxy]-2-[(4-fluorophenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepine,
 4-[[4-[2-[[2-[(2-methylphenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepine-8-yl]oxy]ethyl]-1-piperidinyl]methyl]-1-benzenecarboxyimidamide,
 8-[2-[1-[[4-(4,5-dihydro-1H-2-imidazolyl)phenyl]methyl]-4-piperidinyl]ethoxy]-2-[(2-methylphenyl)methyl]-2,3,4,5-tetrahydro-1H-2-benzazepine,
 2-(phenylmethyl)-8-[2-[1-[[4-(N,N-diethylaminomethyl)phenyl]methyl]-4-piperidinyl]ethoxy]-2,3,4,5-tetrahydro-1H-2-benzazepine,
 2-[(2-methylphenyl)methyl]-8-[2-[1-[[3-(4,5-dihydro-1H-2-imidazolyl)phenyl]methyl]-4-piperidinyl]ethoxy]-2,3,4,5-tetrahydro-1H-2-benzazepine,
 2-[(2-methylphenyl)methyl]-8-[2-[1-[4-(4,5-dihydro-1H-2-imidazolyl)benzoyl]-4-piperidinyl]ethoxy]-2,3,4,5-tetrahydro-1H-2-benzazepine,
 2-(phenylmethyl)-7-[[1-[[4-(4,5-dihydro-1H-2-imidazolyl)phenyl]methyl]-4-piperidinyl]methoxy]-2,3,4,5-tetrahydro-1H-2-benzazepine,
 2-(phenylmethyl)-8-[[1-[[4-(4,5-dihydro-1H-2-imidazolyl)phenyl]methyl]-4-piperidinyl]methoxy]-2,3,4,5-tetrahydro-1H-2-benzazepine,
 2-(phenylmethyl)-8-[2-[1-[[4-(4,5-dihydro-1H-2-imidazolyl)phenyl]methyl]-4-piperidinyl]ethoxy]-2,3,4,5-tetrahydro-1H-2-benzazepine,
 and 2-(phenylmethyl)-8-[2-[1-[(4-dimethylaminophenyl)methyl]-4-piperidinyl]ethoxy]-2,3,4,5-tetrahydro-1H-2-benzazepine,
 or a salt thereof.

13. (Cancelled)

14. (Previously Presented) A process for producing the compound according to claim 1, which comprises reacting a compound represented by the formula:




wherein respective symbols represent the same meanings as those for claim 1 or a salt thereof

with a compound represented by the formula: R^1-Z^1

wherein Z^1 represents a leaving group and R^1 represents the same meaning as that for claim 1 or a salt thereof.


15. (Previously Presented) A compound represented by the formula:



wherein ring A represents benzene ring optionally having a further substituent,

-La- represents $-NR^{3a}-$, $-S-$, $-SO-$, $-SO_2-$, $-SO_2NR^{3a}-$, $-SO_2NHCONR^{3a}-$,

$-SO_2NHC(=NH)NR^{3a}-$, $-C(=S)-$,




or $-CONR^{3a}-$

wherein R^{3a} and R^{3b} represent independently hydrogen atom, cyano group, hydroxy group, amino group, a C_{1-6} alkyl group or a C_{1-6} alkoxy group,

n represents an integer of 0 to 6,

R is hydrogen atom or a hydrocarbon group optionally having a substituent, and may be different in repetition of n,

R^{1a} represents hydrogen atom or a group represented by the formula:



wherein R⁸ represents a hydrocarbon group optionally having a substituent,

R² represents hydrogen atom, an acyl group, a hydrocarbon group optionally having a substituent or a heterocyclic group optionally having a substituent,


X represents a bond,

k and m are each independently an integer of 0 to 4 and k + m = 4,

or a salt thereof.

16. (Cancelled)


17. (Previously Presented) A pharmaceutical composition comprising a compound represented by the formula:



wherein ring A represents benzene ring optionally having a further substituent,

-L- represents -O-, -NR^{3a}-, -S-, -SO-, -SO₂-, -SO₂NR^{3a}-, -SO₂NHCONR^{3a}-,

-SO₂NHC(=NH)NR^{3a}-, -C(=S)-,




or -CONR^{3a}-

wherein R^{3a} and R^{3b} represent independently hydrogen atom,
cyano group, hydroxy group, amino group, a C₁₋₆ alkyl
group or a C₁₋₆ alkoxy group,

n represents an integer of 0 to 6,

R is hydrogen atom or a hydrocarbon group optionally having a substituent, and
may be different in repetition of n,

R¹ represents a hydrocarbon group optionally having a substituent or a group
represented by the formula:



wherein R⁷ represents a hydrocarbon group optionally having a
substituent,

R² represents hydrogen atom, an acyl group, a hydrocarbon group optionally
having a substituent or a heterocyclic group optionally having a
substituent,

X represents a bond,

k and m are each independently an integer of 0 to 4 and k + m = 4,

or a salt thereof

and a pharmacologically acceptable carrier.

Claims 18-21 (Cancelled).

22. (Original) A method for treating obesity and obesity-based diseases, which comprises administering an effective amount of the compound according to claim 1 to a mammal.

Claims 23-42 (Cancelled)

43. (Previously Presented) A method for promoting thermal production in a mammal in need thereof, which comprises administering an effective amount of a compound or a salt thereof according to claim 1 to said mammal.

44. (Previously Presented) A method for promoting lipolysis in a mammal in need thereof, which comprises administering an effective amount of a compound or salt thereof according to claim 1 to said mammal.